Ylisaukko-Oja, Tero Torvinen, Saku Ventola, Hanna Schmidt, Saku Herrala, Sauli Kononoff, Jenni Voutilainen, Markku
Published in
Scandinavian journal of gastroenterology
Objectives: Inflammatory bowel disease (IBD) is associated with a high economic burden to society due to its early onset and chronic character. Here, we set out to characterize healthcare resource utilization and associated costs in Crohn's disease (CD) and ulcerative colitis (UC) patients with infliximab treatment, the most widely used first-line ...
Ashizuka, Shinya Kuroishi, Nobuko Nakashima, Koji Inatsu, Haruhiko Kita, Toshihiro Kitamura, Kazuo
Published in
Internal medicine (Tokyo, Japan)
A 35-year-old man with refractory Crohn's disease showed a loss of response to infliximab after requiring treatment with infliximab at 10 mg/kg together with steroid to maintain remission. His symptoms recurred, and colonoscopy showed extensive active ulcers in the colon. Adrenomedullin therapy was started in addition to the conventional infliximab...
Rinaudo-Gaujous, Mélanie Blasco-Baque, Vincent Miossec, Pierre Gaudin, Philippe Farge, Pierre Roblin, Xavier Thomas, Thierry Paul, Stephane Marotte, Hubert
Published in
Journal of clinical medicine
Rheumatoid arthritis and periodontal disease are associated together, but the effect of therapy provided for one disease to the second one remained under-investigated. This study investigated effect of infliximab therapy used to treat rheumatoid arthritis (RA) on various biomarkers of periodontal disease (PD) severity including serologies of Porphy...
Oskardmay, Ashley N Miles, J Alex Sayed, Christopher J
Published in
Journal of the American Academy of Dermatology
Few data exist to guide infliximab dosing in hidradenitis suppurativa (HS). To determine optimal infliximab dosing for patients with HS based on treatment response and achievement of stable dosing. Retrospective cohort study of 52 patients with HS treated with infliximab. Primary outcome was achievement of stable dosing regimen for at least 8 weeks...
Pudipeddi, Aviv Kariyawasam, Viraj Haifer, Craig Baraty, Brandon Paramsothy, Sudarshan Leong, Rupert Wl
Published in
Expert opinion on drug safety
Medications in treating Crohn's disease (CD) have evolved over the last two decades, particularly with the use of biologic agents. There are, however, concerns about the safety and adverse events associated with these medications. The authors review the safety profile of immunosuppressive medications used in Crohn's disease in adult patients. The a...
Nemoz, Benjamin Ternant, David Bailly, Sébastien Gautier-Veyret, Elodie Jourdil, Jean-François Bonaz, Bruno Stanke-Labesque, Françoise
Published in
British journal of clinical pharmacology
Therapeutic drug monitoring (TDM) of infliximab (IFX) appears to be beneficial for patients with inflammatory bowel disease (IBD). However, the recommended target concentrations depend partly on the method used to quantify IFX. Since we recently developed a liquid chromatography-tandem mass spectrometry method to quantify IFX, we aimed to determine...
Dreesen, Erwin Faelens, Ruben Van Assche, Gert Ferrante, Marc Vermeire, Séverine Gils, Ann Bouillon, Thomas
Published in
British journal of clinical pharmacology
The therapeutic failure of infliximab therapy in patients with ulcerative colitis remains a challenge even 2 decades after its approval. Therapeutic drug monitoring (TDM) has shown value during maintenance therapy, but induction therapy has still not been explored. Patients may be primary nonresponders or underexposed with the standard dosing regim...
Faghihi, Homa Najafabadi, Abdolhossein Rouholamini Daman, Zahra Ghasemian, Elham Montazeri, Hamed Vatanara, Alireza
Published in
AAPS PharmSciTech
The airways are verified as a relevant route to improve antibody therapeutic index with superior lung concentration but limited passage into systemic blood stream. The current research aimed to process spray-dried (SD) powder of Infliximab to assess the feasibility of respiratory delivery of antibody for local suppression of lung-secreted tumor nec...
Zhang, Hao Chi Luo, Wenyi Wang, Yinghong
Published in
Journal for ImmunoTherapy of Cancer
BackgroundImmune checkpoint inhibitors (ICPIs), used to treat different advanced malignancies, are associated with a wide range of immune-related adverse reactions (irAEs) that deserve close monitoring of patients. Gastrointestinal reactions and hepatotoxicity may occur, which warrant careful evaluation to confirm the etiology and attribution to IC...
Zhang, Qi Wei Shen, Jun Zheng, Qing Ran, Zhi Hua
Published in
Journal of digestive diseases
To determine the potential predictors of loss of response (LOR) to infliximab (IFX) maintenance therapy for adult patients with Crohn's disease (CD). We searched for English-language articles published between 1990 and March 2017 in PubMed, Embase, and the Cochrane Library. After identifying eligible studies, data extraction was performed independe...
